Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dihydroartemisinin + piperaquine + metronidazole
- Development stage
- Preclinical
- Lead developer
- Alfasigma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination antimalarial and antiprotozoal medication consisting of dihydroartemisinin (an artemisinin derivative), piperaquine (a long-acting antimalarial), and metronidazole (an antibiotic and antiprotozoal agent). This combination is used for treating patients with both malaria and intestinal protozoal infections. Dihydroartemisinin-piperaquine inhibits the P. falciparum parasite's haem detoxification pathway, while metronidazole is effective against intestinal protozoa such as Entamoeba histolytica.
02
Targets
HemeNeuraminidase
Beyond the preview
Go deeper on dihydroartemisinin + piperaquine + metronidazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dihydroartemisinin + piperaquine + metronidazole.